Your browser doesn't support javascript.
loading
Toward the Development of a Tissue Engineered Gradient Utilizing CRISPR-Guided Gene Modulation.
Weston, Jacob D; Austin, Brooke; Levis, Hunter; Zitnay, Jared; Weiss, Jeffrey A; Lawrence, Brandon; Bowles, Robby D.
Afiliação
  • Weston JD; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.
  • Austin B; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.
  • Levis H; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.
  • Zitnay J; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.
  • Weiss JA; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.
  • Lawrence B; Department of Orthopedic Surgery, University of Utah, Salt Lake City, Utah, USA.
  • Bowles RD; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.
Tissue Eng Part A ; 30(17-18): 525-535, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38323556
ABSTRACT
Cellular, compositional, and mechanical gradients are found throughout biological tissues, especially in transition zones between tissue types. Yet, strategies to engineer such gradients have proven difficult due to the complex nature of these tissues. Current strategies for tissue engineering complex gradients often utilize stem cells; however, these multipotent cells require direction from environmental cues, which can be difficult to control both in vitro and in vivo. In this study, we utilize clustered regularly-interspaced short palindromic repeats (CRISPR)-guided gene modulation to direct the differentiation of multipotent adipose-derived stem cells (ASCs) to demonstrate the effectiveness of CRISPR-engineered cells in tissue engineering applications. Specifically, we screen CRISPR-interference (CRISPRi) constructs targeting the promotors of selected osteogenic inhibitors and demonstrate that ASC osteogenic differentiation and mineral deposition can be regulated with CRISPRi targeting of Noggin without the use of exogenous growth factors in tissue engineered constructs. As a proof of concept, we combine three technologies developed out of our laboratories to demonstrate the controlled deposition of these engineered cells in a gradient with CRISPR-activation multiplex-engineered aggrecan/collagen type-II-chondrogenic ASCs on a high density anisotropic type I collagen construct to create a cell and tissue gradient similar to the fibrocartilage-to-mineralized-fibrocartilage gradient in the enthesis. Our results display the promise of CRISPR-engineered ASCs to produce tissue gradients, similar to what is observed in native tissue.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Engenharia Tecidual Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Engenharia Tecidual Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article